YahooSeptember 22, 2026 at 9:05 AM NYLast Month
Jaguar Health Receives Fee Waivers from FDA
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027SAN FRANCISCO, CA / ACCESS Newswire / September 22, 2026 / (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that the U. Food and Drug Administration (FDA) has granted Napo's request for a waiver of the fee associated with the Pres
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
